Novartis

News

Strike two for Novartis' lung cancer antibody canakinumab

Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti

News

FDA clears Roche's Susvimo implant for eye disease wet AMD

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular inj

News

Female doctor with the stethoscope holding heart

Novartis-backed project mobilises patient power against hear...

Novartis has joined forces with a group representing cardiovascular disease patients organisations to push for changes in how health systems handle the world's number one killer.

News

Consternation as NICE rejects Janssen MS drug Ponvory

NICE has delivered its first verdict on NHS funding of Janssen's oral multiple sclerosis drug Ponvory, and it's not good news for patients with the disease waiting for new treatment options

News

Joy as sickle cell patients get access to Novartis' Adakveo ...

People living with sickle cell disease (SCD) in England and Wales will be able to get access to treatment with Novartis' Adakveo, thanks to a special arrangement between the drugmaker and N

R&D

Novartis’ Amit Nastik on COVID’s supply chain impact: the ph...

Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations.<

Strike two for Novartis' lung cancer antibody canakinumab

FDA clears Roche's Susvimo implant for eye disease wet AMD

Novartis-backed project mobilises patient power against hear...

Consternation as NICE rejects Janssen MS drug Ponvory

Joy as sickle cell patients get access to Novartis' Adakveo ...

Novartis’ Amit Nastik on COVID’s supply chain impact: the ph...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks